Ключевые слова
Аннотация
Altsgeymer kasalligi kognitiv funksiyalarni asta-sekin yo‘qotish, xotira va tafakkur buzilishi bilan kechadigan neyrodejenerativ kasallikdir. Kasallikning erta bosqichida aniqlanishi bemorning hayot sifatini yaxshilash va davolash samaradorligini oshirish imkonini beradi. Ushbu maqolada Altsgeymer kasalligining patogenezi, klinik belgilarining rivojlanishi, erta diagnostika usullari va ularning afzalliklari tahlil qilinadi.
Библиографические ссылки
2024 Revised Criteria: “Revised criteria for diagnosis and staging of Alzheimer’s disease.” Alzheimer’s & Dementia (2024) va ochiq ko‘rinishdagi sharh. alz-journals.onlinelibrary.wiley.comPMC
Alzheimer’s Association: “Criteria for Diagnosis and Staging of AD (2024).” Alzheimer’s Association
Plazma p-tau217 bo‘yicha “head-to-head” tadqiqotlar: Brain (2025) va PMC sharhi. Oxford AcademicPMC
Nature Medicine: “Blood plasma %p-tau217 clinically equivalent/superior to CSF tests.” (2024). Nature
Nature Medicine (2025): p-tau217 + GFAP/NfL kombinatsiyalarining prognoz qiymati. Nature
MoCA vs MMSE: BMC Psychiatry (2021) va 2024 taqqoslovchi tadqiqot. BioMed CentralНаучный Дайрект
Imaging AUC (2025): Amyloid va Tau PET uchun yangilangan qo‘llanma (Journal of Nuclear Medicine). SNM Journals
MRI roli va avtomatlashtirish: sharh va 7T submaydon ishlari. PMC+1
FDG-PET: klassik AD gipometabolizm namunasi bo‘yicha sharhlar. PMCBioMed Central
AI & Digital biomarkers: NIA xabari (AI-nutq, 78% aniqlik) va 2025 skoping sharh. nia.nih.govPMC
Genetika: Genetik maslahat/PSEN1/2/APP bo‘yicha amaliy yo‘riqnomalar; APOE xavf, ammo tashxis qo‘ymaydi